UNSPSC 51422003: Sermorelin acetate

This classification denotes a growth hormone-releasing hormone analogue with the molecular formula C149H246N44O42S.C2H4O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00IBG87IQW, chemically known as 29-l-argininamide-30-de-l-glutamine-31-de-l-glutamine-32-deglycine-33-de-l-glutamic acid-34-de-l-serine-35-de-l-asparagine-36-de-l-glutamine-37-de-l-glutamic acid-38-de-l-arginine-39-deglycine-40-de-l-alanine-41-de-l-arginine-42-de-l-alanine-43-de-l-arginine-44-de-l-leucinamidegrowth hormone-releasing factor (human pancreatic islet), acetate (salt), hydrate but generally known as sermorelin acetate, which bears US NIH Compound Identifier 16132412.

UNSPSC 51422003 Sermorelin acetate is a Commodity code nominally identifying a synthetic growth-hormone-releasing peptide, but recent state and local activity does not match this scope. The two recent opportunities tagged under this code involve procurement of naloxone (an opioid antagonist) and safe drug deactivation systems by Seminole County, Florida, and a request for information from the Texas Health and Human Services Commission regarding direct-to-manufacturer prescription programs — neither of which involves sermorelin acetate or growth-hormone therapeutics. The mismatch suggests either a classification error in the opportunities themselves or a drift in how this code is being applied in the state and local system; the code shows little relevant recent activity aligned with its nominal pharmaceutical product scope.

The Seminole County solicitation (IFB 60459723LAS, posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the county's community health building in Sanford and delivery costs included in bids. The Texas HHS RFI (HHS0017013, posted April 3, 2026) represented early-stage market research into direct-to-manufacturer prescription programs for state pharmacy benefit management, gathering vendor capabilities before issuing formal solicitation documents. Neither opportunity reflects procurement activity under the code's stated pharmaceutical category. Firms evaluating this code should monitor whether tagging practices clarify or whether actual sermorelin-acetate solicitations emerge from state and local health agencies, clinical procurement offices, or prison health systems — the likeliest buyers of this therapeutic class.